Schiff Nutrition International, Inc. Appoints Richard G. Wolford to the Board of Directors
08 Setembro 2011 - 8:05AM
Business Wire
Schiff Nutrition International, Inc., (NYSE: WNI), appointed
former Chairman, President and Chief Executive Officer of Del Monte
Foods, Richard G. Wolford, 66, to its board of directors.
Eric Weider, Schiff Nutrition’s chairman, said: “Rick brings
significant experience to our team. While at Del Monte Foods, he
led efforts to develop and purchase strong and growing brand
equities. The company grew from a $1 billion consumer foods
business into one of the country’s largest and most well-known
producers, distributors and marketers of premium quality, branded
food and pet products with close to $4 billion in revenue.”
“The board and I have set important goals to drive shareholder
value,” stated Tarang Amin, president and chief executive officer
of Schiff Nutrition. “We look forward to Rick’s insight as we focus
on our long-term growth strategies.”
Wolford added, “With its strong management team, I believe
Schiff Nutrition is well positioned to pursue its objectives of
building premium brands, leading innovation, expanding the channel
and geographic footprint of the company, pursuing acquisitions, and
driving world-class operations. I am excited to join this talented
and motivated team at this pivotal juncture.”
In March 2011, Richard G. Wolford retired as Chairman, President
and Chief Executive Officer of Del Monte. He had served as Chief
Executive Officer since 1997 and Chairman since 2000. Wolford began
his career in the food industry joining Dole Foods in 1967.
Beginning in finance, he held a range of international management
positions, and in 1982, he began his five-year tenure as President
of Dole Packaged Foods. In 1987, Wolford joined with venture
capital investors to invest in and develop businesses in the food
industry.
Wolford served the Grocery Manufacturers Association (GMA) as
Chairman of the board of directors from 2010 until 2011, Vice
Chairman of GMA from 2008 until 2010 and as Chairman of GMA’s
Industry Affairs Council from 2005 until 2010. He also served on
the board of directors for the Consumer Goods Forum (the global
association of Consumer Packaged Goods companies) and the Bay Area
Council. Wolford graduated from Harvard University with a degree in
Economics.
About Schiff Nutrition
Schiff Nutrition International, Inc. develops, manufactures,
markets and distributes branded and private label vitamins,
nutritional supplements and nutrition bars in the United States and
throughout the world. Schiff’s portfolio of well-known brands
includes Schiff Move Free®, Schiff® Vitamins, Schiff MegaRed®,
Schiff Mega-D3®, Tiger's Milk®, Schiff Sustenex®, and Schiff
Digestive Advantage®. To learn more about Schiff, please visit the
web site www.schiffnutrition.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 that are based
on management’s beliefs and assumptions, current expectations,
estimates, and projections. These statements are subject to known
and unknown risks and uncertainties, certain of which are beyond
the company’s ability to control or predict, and therefore, actual
results may differ materially. Any forward-looking statements are
made pursuant to the Private Securities Litigation Reform Act of
1995 and, as such, speak only as of the date hereof. Schiff
Nutrition disclaims any obligation to update any forward-looking
statements whether as a result of new information, future events or
otherwise. You are cautioned not to place undue reliance on these
forward-looking statements.
Important factors that may cause actual results of Schiff
Nutrition to differ materially from those expressed or implied by
such forward-looking statements include, but are not limited to:
dependence on sales of Schiff Move Free product and the joint care
category, dependence on sales of Schiff MegaRed product, dependence
on individual customers, adverse publicity or consumer perception
regarding our nutritional supplements and/or their ingredients,
similar products distributed by other companies or the nutritional
supplement industry generally, the impact of competitive products
and pricing pressure (including expansion of private label
products), the inability to successfully bid on new and existing
private label business, the impact of raw material pricing,
availability and quality (particularly relating to joint care
products and ingredients from third-party suppliers outside the
United States, including China), claims that our products infringe
the intellectual property rights of others, the inability to
enforce or protect our intellectual property rights and proprietary
techniques against infringement, the inability to successfully
launch and maintain sales (especially in the joint care and omega-3
categories) outside of the United States while maintaining the
integrity of the products sold and complying with local
regulations, the inability to appropriately respond to changing
consumer preferences and demand for new products, the inability to
gain or maintain market distribution for new products or product
enhancements, including products in the probiotic space, litigation
and government or administrative regulatory action in the United
States and internationally, including FDA enforcement and product
liability claims, the inability or increased cost to obtain
sufficient levels of product liability and general insurance, the
inability to comply with existing or new regulations, both in the
United States and abroad, and adverse actions regarding product
formulation, claims or advertising, product recalls or a
significant amount of product returns, dependence on a single
manufacturing facility and potential disruptions of our
manufacturing operations, the inability to find strategic
transaction opportunities or the inability to successfully
consummate or integrate a strategic transaction (including the
inability to successfully integrate the assets recently acquired
from Ganeden), the inability to maintain or attract key personnel,
interruptions to our information technology systems, control by our
principal stockholders, and other factors indicated from time to
time in the company’s SEC reports, copies of which are available
upon request from the company’s investor relations department or
may be obtained at the SEC's web site (www.sec.gov). These risks and uncertainties should
be carefully considered before making an investment decision with
respect to shares of our common stock.
Schiff Nutrit (NYSE:WNI)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Schiff Nutrit (NYSE:WNI)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024